Modulation of HIV-1 immunity by adjuvants

Current Opinion in HIV and AIDS

Volumn 9, Issue 3, 2014, Pages 242-249

  Anthony Moody, M ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Adjuvants; antibodies; antigens peptides epitopes; B cells; HIV 1; vaccines

Indexed keywords

ANTIGEN; BACTERIAL VECTOR; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOLOGICAL ADJUVANT; NEUTRALIZING ANTIBODY; PATTERN RECOGNITION RECEPTOR; TOLL LIKE RECEPTOR; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY;

ANTIBODY RESPONSE; ANTIBODY TITER; DNA VECTOR; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOMODULATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; ANIMAL; DISEASE MODEL; HIV INFECTIONS; IMMUNOLOGY;

ADJUVANTS, IMMUNOLOGIC; AIDS VACCINES; ANIMALS; ANTIBODIES, NEUTRALIZING; DISEASE MODELS, ANIMAL; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS;

EID: 84898546111     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0000000000000052     Document Type: Review

References (95)

1. Reed SG, Orr MT, Fox CB. Key roles of adjuvants in modern vaccines. Nat Med 2013; 19:1597-1608.
2. Barouch DH, Letvin NL, Seder RA. The role of cytokine DNAs as vaccine adjuvants for optimizing cellular immune responses. Immunol Rev 2004; 202:266-274.
3. Coffman RL, Sher A, Seder RA. Vaccine adjuvants: putting innate immunity to work. Immunity 2010; 33:492-503.
4. Loré K, Karlsson Hedestam GB. Novel adjuvants for Bcell immune responses. Curr Opin HIV AIDS 2009; 4:441-446.
5. De Gregorio E, Ulmer J, Caproni E, Ulmer JB. Vaccine adjuvants: mode of action. Front Immun 2013; 4:214.
6. Edelman R, Tacket CO. Adjuvants. Int Rev Immunol 1990; 7:51-66.
7. Morrow MP, Weiner DB. Cytokines as adjuvants for improving anti-HIV responses. AIDS 2008; 22: 333-338.
8. Calarota SA, Weiner DB. Enhancement of human immunodeficiency virus type 1-DNA vaccine potency through incorporation of T-helper 1 molecular adjuvants. Immunol Rev 2004; 199:84-99.
9. Gallo RC. A reflection on HIV/AIDS research after 25 years. Retrovirology 2006; 3:72.
10. Zagury D, Bernard J, Cheynier R, et al. A group specific anamnestic immune reaction against HIV-1 induced by a candidate vaccine against AIDS. Nature 1988; 332:728-731.
11. Zagury D, Lé onard R, Fouchard M, et al. Immunization against AIDS in humans. Nature 1987; 326:249-250.
12. Niedrig M, Gregersen JP, Fultz PN, et al. Immune response of chimpanzees after immunization with the inactivated whole immunodeficiency virus (HIV-1), three different adjuvants and challenge. Vaccine 1993; 11:67-74.
13. LaCasse RA, Follis KE, Trahey M, et al. Fusion-competent vaccines: broad neutralization of primary isolates of HIV. Science 1999; 283:357-362.
14. Nunberg JH. Retraction. Science 2002; 296:1025.
15. Pyle SW, Morein B, Bess JW, et al. Immune response to immunostimulatory complexes (ISCOMs) prepared from human immunodeficiency virus type 1 (HIV-1) or the HIV-1 external envelope glycoprotein (gp120). Vaccine 1989; 7:465-473.
16. Belshe RB, Clements ML, Dolin R, et al. Safety and immunogenicity of a fully glycosylated recombinant gp160 human immunodeficiency virus type 1 vaccine in subjects at low risk of infection. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group Network. J Infect Dis 1993; 168:1387-1395.
17. Pitisuttithum P, Gilbert P, Gurwith M, et al. Bangkok Vaccine Evaluation Group: randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis 2006; 194:1661-1671.
18. Flynn NM, Forthal DN, Harro CD, et al. rgp120 HIV Vaccine Study Group: Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 2005; 191:654-665.
19. Mannhalter JW, Pum M, Wolf HM, et al. Immunization of chimpanzees with the HIV-1 glycoprotein gp160 induces long-lasting T-cell memory. AIDS Res Hum Retroviruses 1991; 7:485-493.
20. Levi M, Rudén U, Birx D, et al. Effects of adjuvants and multiple antigen peptides on humoral and cellular immune responses to gp160 of HIV-1. J Acquir Immune Defic Syndr 1993; 6:855-864.
21. Ronco J, Dedieu JF, Marie FN, et al. High-titer HIV-1 neutralizing antibody response of rhesus macaques to gp160 and env peptides. AIDS Res Hum Retroviruses 1992; 8:1117-1123.
22. Wu JY, Gardner BH, Murphy CI, et al. Saponin adjuvant enhancement of antigen-specific immune responses to an experimental HIV-1 vaccine. J Immunol 1992; 148:1519-1525.
23. Turánek J, Toman M, Novák J, et al. Adjuvant effect of liposomes and adamantylamide dipeptide on antigenicity of entrapped synthetic peptide derived from HIV-1 transmembrane region glycoprotein gp41. Immunol Lett 1994; 39: 157-161.
24. Stieneker F, Kersten G, van Bloois L, et al. Comparison of 24 different adjuvants for inactivated HIV-2 split whole virus as antigen in mice. Induction of titres of binding antibodies and toxicity of the formulations. Vaccine 1995; 13:45-53.
25. Ahlers JD, Dunlop N, Pendleton CD, et al. Candidate HIV type 1 multi-determinant cluster peptide-P18MN vaccine constructs elicit type 1 helper T cells, cytotoxic T cells, and neutralizing antibody, all using the same adjuvant immunization. AIDS Res Hum Retroviruses 1996; 12:259-272.
26. Cleland JL, Barron L, Daugherty A, et al. Development of a single-shot subunit vaccine for HIV-1.3. Effect of adjuvant and immunization schedule on the duration of the humoral immune response to recombinant MN gp120 J Pharm Sci 1996; 85:1350-1357.
27. Perraut R, Chouteau P, Moog C, et al. Immunogenicity of HIV-1LAI gp160 and env peptides in squirrel monkey Saimiri sciureus using alumine and experimental adjuvants. Clin Exp Immunol 1996; 106:434-441.
28. Peet NM, McKeating JA, Ramos B, et al. Comparison of nucleic acid and protein immunization for induction of antibodies specific for HIV-1 gp120. Clin Exp Immunol 1997; 109:226-232.
29. Sauzet JP, Moog C, Krivine A, et al. Adjuvant is required when using Env lipopeptide construct to induce HIV type 1-specific neutralizing antibody responses in mice in vivo. AIDS Res Hum Retroviruses 1998; 14:901-909.
30. Verschoor EJ, Mooij P, Oostermeijer H, et al. Comparison of immunity generated by nucleic acid-, MF59-, and ISCOM-formulated human immunodeficiency virus type 1 vaccines in Rhesus macaques: evidence for viral clearance. J Virol 1999; 73:3292-3300.
31. Keefer MC, Wolff M, Gorse GJ, et al. Safety profile of phase I and II preventive HIV type 1 envelope vaccination: experience of the NIAID AIDS Vaccine Evaluation Group. AIDS Res Hum Retroviruses 1997; 13:1163-1177.
32. Burton DR, Desrosiers RC, Doms RW, et al. Public health. A sound rationale needed for phase III HIV-1 vaccine trials. Science 2004; 303:316-1316.
33. Belshe R, Franchini G, Girard MP, et al. Support for the RV144 HIV Vaccine Trial: new series. Science 2004; 305:177-180.
34. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009; 361:2209-2220.
35. Robb ML, Rerks-Ngarm S, Nitayaphan S, et al. Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a posthoc analysis of the Thai phase 3 efficacy trial RV 144. Lancet Infect Dis 2012; 12:531-537.
36. Xin KQ, Hamajima K, Sasaki S, et al. Intranasal administration of human immunodeficiency virus type-1 (HIV-1) DNA vaccine with interleukin-2 expression plasmid enhances cell-mediated immunity against HIV-1. Immunology 1998; 94:438-444.
37. Xin KQ, Hamajima K, Sasaki S, et al. IL-15 expression plasmid enhances cell-mediated immunity induced by an HIV-1 DNA vaccine. Vaccine 1999; 17:858-866.
38. Xin KQ, Lu Y, Hamajima K, et al. Immunization of RANTES expression plasmid with a DNA vaccine enhances HIV-1-specific immunity. Clin Immunol 1999; 92:90-96.
39. Stone GW, Barzee S, Snarsky V, et al. Multimeric soluble CD40 ligand and GITR ligand as adjuvants for human immunodeficiency virus DNA vaccines. J Virol 2006; 80:1762-1772.
40. Robinson HL, Montefiori DC, Villinger F, et al. Studies on GM-CSF DNA as an adjuvant for neutralizing Ab elicited by a DNA/MVA immunodeficiency virus vaccine. Virology 2006; 352:285-294.
41. Qiu J-T, Chang T-C, Lin C-T, et al. Novel codon-optimized GM-CSF gene as an adjuvant to enhance the immunity of a DNA vaccine against HIV-1 Gag. Vaccine 2007; 25:253-263.
42. Nimal S, Heath AW, Thomas MS. Enhancement of immune responses to an HIV gp120 DNA vaccine by fusion to TNF alpha cDNA. Vaccine 2006; 24:3298-3308.
43. Nayak BP, Sailaja G, Jabbar AM. Augmenting the immunogenicity of DNA vaccines: role of plasmid-encoded Flt-3 ligand, as a molecular adjuvant in genetic vaccination. Virology 2006; 348:277-288.
44. Lu Y, Xin KQ, Hamajima K, et al. Macrophage inflammatory protein-1alpha (MIP-1alpha) expression plasmid enhances DNA vaccine-induced immune response against HIV-1. Clin Exp Immunol 1999; 115:335-341.
45. Kanagavelu SK, Snarsky V, Termini JM, et al. Soluble multitrimeric TNF superfamily ligand adjuvants enhance immune responses to a HIV-1 Gag DNA vaccine. Vaccine 2012; 30:691-702.
46. Castaldello A, Sgarbanti M, Marsili G, et al. Interferon regulatory factor-1 acts as a powerful adjuvant in the DNA based vaccination. J Cell Physiol 2010; 224:702-709.
47. Bu Z, Ye L, Skeen MJ, et al. Enhancement of immune responses to an HIV env DNA vaccine by a C-terminal segment of listeriolysin O. AIDS Res Hum Retroviruses 2003; 19:409-420.
48. Calarota SA, Dai A, Trocio JN, et al. IL-15 as memory T-cell adjuvant for topical HIV-1 DermaVir vaccine. Vaccine 2008; 26:5188-5195.
49. Barouch DH, Santra S, Tenner-Racz K, et al. Potent CD4+ T cell responses elicited by a bicistronic HIV-1 DNA vaccine expressing gp120 and GM-CSF. J Immunol 2002; 168:562-568.
50. Xu R, Megati S, Roopchand V, et al. Comparative ability of various plasmid-based cytokines and chemokines to adjuvant the activity of HIV plasmid DNA vaccines. Vaccine 2008; 26:4819-4829.
51. Sun J, Hou J, Li D, et al. Enhancement of HIV-1 DNA vaccine immunogenicity by BCG-PSN, a novel adjuvant. Vaccine 2013; 31:472-479.
52. Aggarwal P, Pandey RM, Seth P. Augmentation of HIV-1 subtype C vaccine constructs induced immune response in mice by CpG motif 1826-ODN. Viral Immunol 2005; 18:213-223.
53. Toda S, Ishii N, Okada E, et al. HIV-1-specific cell-mediated immune responses induced by DNA vaccination were enhanced by mannan-coated liposomes and inhibited by antiinterferon-gamma antibody. Immunology 1997; 92:111-117.
54. Zuber AK, Brave A, Engström G, et al. Topical delivery of imiquimod to a mouse model as a novel adjuvant for human immunodeficiency virus (HIV) DNA. Vaccine 2004; 22:1791-1798.
55. Liu J, Kjeken R, Mathiesen I, Barouch DH. Recruitment of antigen-presenting cells to the site of inoculation and augmentation of human immunodeficiency virus type 1 DNA vaccine immunogenicity by in vivo electroporation. J Virol 2008; 82:5643-5649.
56. Yin J, Dai A, Lecureux J, et al. High antibody and cellular responses induced to HIV-1 clade C envelope following DNA vaccines delivered by electroporation. Vaccine 2011; 29:6763-6770.
57. Hirao LA, Wu L, Khan AS, et al. Combined effects of IL-12 and electroporation enhances the potency of DNA vaccination in macaques. Vaccine 2008; 26:3112-3120.
58. Kalams SA, Parker SD, Elizaga M, et al. Safety and comparative immuno-genicity of an HIV-1 DNA vaccine in combination with plasmid interleukin 12 and impact of intramuscular electroporation for delivery. J Infect Dis 2013; 208:818-829.
59. Abaitua F, Rodŕiguez JR, Garzón A, et al. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma. Virus Res 2006; 116:11-20.
60. Gherardi MM, Ramírez JC, Rodŕiguez D, et al. IL-12 delivery from recombinant vaccinia virus attenuates the vector and enhances the cellular immune response against HIV-1 Env in a dose-dependent manner. J Immunol 1999; 162:6724-6733.
61. Liu J, Yu Q, Stone GW, et al. CD40L expressed from the canarypox vector, ALVAC, can boost immunogenicity of HIV-1 canarypox vaccine in mice and enhance the in vitro expansion of viral specific CD8+ T cell memory responses from HIV-1-infected and HIV-1-uninfected individuals. Vaccine 2008; 26:4062-4072.
62. Liu J, Ngai N, Stone GW, et al. The adjuvancy of OX40 ligand (CD252) on an HIV-1 canarypox vaccine. Vaccine 2009; 27:5077-5084.
63. Faul EJ, Wanjalla CN, McGettigan JP, Schnell MJ. Interferon-beta expressed by a rabies virus-based HIV-1 vaccine vector serves as a molecular adjuvant and decreases pathogenicity. Virology 2008; 382:226-238.
64. Gómez CE, Nájera JL, Sánchez R, et al. Multimeric soluble CD40 ligand (sCD40L) efficiently enhances HIV specific cellular immune responses during DNA prime and boost with attenuated poxvirus vectors MVA and NYVAC expressing HIV antigens. Vaccine 2009; 27:3165-3174.
65. Naito T, Kaneko Y, Kozbor D. Oral vaccination with modified vaccinia virus Ankara attached covalently to TMPEG-modified cationic liposomes overcomes preexisting poxvirus immunity from recombinant vaccinia immunization. J Gen Virol 2007; 88:61-70.
66. Hansen B, Malyala P, Singh M, et al. Effect of the strength of adsorption of HIV 1 SF162dV2gp140 to aluminum-containing adjuvants on the immune response. J Pharm Sci 2011; 100:3245-3250.
67. Dorosko SM, Ayres SL, Connor RI. Induction of HIV-1 MPR(649-684)-specific IgA and IgG antibodies in caprine colostrum using a peptide-based vaccine. Vaccine 2008; 26:5416-5422.
68. Li Y, Svehla K, Mathy NL, et al. Characterization of antibody responses elicited by human immunodeficiency virustype1primaryisolate trimeric and monomeric envelope glycoproteins in selected adjuvants. J Virol 2006; 80:1414-1426.
69. Mörner A, Douagi I, Forsell MNE, et al. Human immunodeficiency virus type 1 env trimer immunization of macaques and impact of priming with viral vector or stabilized core protein. J Virol 2009; 83:540-551.
70. Leroux-Roels I, Koutsoukos M, Clement F, et al. Strong and persistent CD4+ T-cell response in healthy adults immunized with a candidate HIV-1 vaccine containing gp120, Nef and Tat antigens formulated in three adjuvant systems. Vaccine 2010; 28:7016-7024.
71. Goepfert PA, Tomaras GD, Horton H, et al. Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multiprotein recombinant vaccine in uninfected human volunteers. Vaccine 2007; 25:510-518.
72. Burke B, Gó mez-Román VR, Lian Y, et al. Neutralizing antibody responses to subtype B and C adjuvanted HIV envelope protein vaccination in rabbits. Virology 2009; 387:147-156.
73. Lai RPJ, Seaman MS, Tonks P, et al. Mixed adjuvant formulations reveal a new combination that elicit antibody response comparable to Freund's adjuvants. PLoS One 2012; 7:e35083.
74. Moody MA, Santra S, Vandergrift NA, et al. TLR-7/8 and 9 agonists cooperate to enhance HIV-1 envelope antibody responses in rhesus macaques. J Virol 2014; 88:3329-3339.
75. Singh SK, Bisen PS. Adjuvanticity of stealth liposomes on the immunogenicity of synthetic gp41 epitope of HIV-1. Vaccine 2006; 24:4161-4166.
76. MacDonald AJ, Cao L, He Y, et al. rOv-ASP-1, a recombinant secreted protein of the helminth Onchocerca volvulus, is a potent adjuvant for inducing antibodies to ovalbumin, HIV-1 polypeptide and SARS-CoV peptide antigens. Vaccine 2005; 23:3446-3452.
77. Wintsch J, Chaignat CL, Braun DG, et al. Safety and immunogenicity of a genetically engineered human immunodeficiency virus vaccine. J Infect Dis 1991; 163:219-225.
78. Keefer MC, Graham BS, McElrath MJ, et al. Safety and immunogenicity of Env 2-3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59. NIAID AIDS Vaccine Evaluation Group. AIDS Res Hum Retroviruses 1996; 12:683-693.
79. McCormack S, Tilzey A, Carmichael A, et al. A phase I trial in HIV negative healthy volunteers evaluating the effect of potent adjuvants on immunogenicity of a recombinant gp120W61D derived from dual tropic R5X4 HIV-1ACH320. Vaccine 2000; 18:1166-1177.
80. Pitisuttithum P, Berman PW, Phonrat B, et al. Phase I/II study of a candidate vaccine designed against the B and E subtypes of HIV-1. J Acquir Immune Defic Syndr 2004; 37:1160-1165.
81. Yoshino N, Lü FX-S, Fujihashi K, et al. A novel adjuvant for mucosal immunity to HIV-1 gp120 in nonhuman primates. J Immunol 2004; 173:6850-6857.
82. Sundling C, Schön K, Mörner A, et al. CTA1-DD adjuvant promotes strong immunity against human immunodeficiency virus type 1envelope glycoproteins following mucosal immunization. J Gen Virol 2008; 89:2954-2964.
83. Nordone SK, Peacock JW, Kirwan SM, Staats HF. Capric acid and hydroxypropylmethylcellulose increase the immunogenicity of nasally administered peptide vaccines. AIDS Res Hum Retroviruses 2006; 22:558-568.
84. Egan MA, Chong SY, Hagen M, et al. A comparative evaluation of nasal and parenteral vaccine adjuvants to elicit systemic and mucosal HIV-1 peptide-specific humoral immune responses in cynomolgus macaques. Vaccine 2004; 22:3774-3788.
85. Bradney CP, Sempowski GD, Liao H-X, et al. Cytokines as adjuvants for the induction of antihuman immunodeficiency virus peptide immunoglobulin G (IgG) and IgA antibodies in serum and mucosal secretions after nasal immunization. J Virol 2002; 76:517-524.
86. Bielinska AU, Janczak KW, Landers JJ, et al. Nasal immunization with a recombinant HIV gp120 and nanoemulsion adjuvant produces Th1 polarized responses and neutralizing antibodies to primary HIV type 1 isolates. AIDS Res Hum Retroviruses 2008; 24:271-281.
87. Borsutzky S, Fiorelli V, Ebensen T, et al. Efficient mucosal delivery of the HIV-1 Tat protein using the synthetic lipopeptide MALP-2 as adjuvant. Eur J Immunol 2003; 33:1548-1556.
88. Borsutzky S, Ebensen T, Link C, et al. Efficient systemic and mucosal responses against the HIV-1 Tat protein by prime/boost vaccination using the lipopeptide MALP-2 as adjuvant. Vaccine 2006; 24:2049-2056.
89. Cranage MP, Fraser CA, Cope A, et al. Antibody responses after intravaginal immunisation with trimeric HIV-1 CN54 clade C gp140 in Carbopol gel are augmented by systemic priming or boosting with an adjuvanted formulation. Vaccine 2011; 29:1421-1430.
90. Van Roey GA, Arias MA, Tregoning JS, et al. Thymic stromal lymphopoietin (TSLP) acts as a potent mucosal adjuvant for HIV-1 gp140 vaccination in mice. Eur J Immunol 2012; 42:353-363.
91. Pattani A, McKay PF, Garland MJ, et al. Microneedle mediated intradermal delivery of adjuvanted recombinant HIV-1 CN54gp140 effectively primes mucosal boost inoculations. J Control Release 2012; 162:529-537.
92. Rosario M, Borthwick N, Stewart-Jones GB, et al. Prime-boost regimens with adjuvanted synthetic long peptides elicit T cells and antibodies to conserved regions of HIV-1 in macaques. AIDS 2012; 26:275-284.
93. Barnett SW, Burke B, Sun Y, et al. Antibody-mediated protection against mucosal simian-human immunodeficiency virus challenge of macaques immunized with alphavirus replicon particles and boosted with trimeric envelope glycoprotein in MF59 adjuvant. J Virol 2010; 84:5975-5985.
94. Raya NE, Quintana D, Carrazana Y, et al. A prime-boost regime that combines Montanide ISA720 and Alhydrogel to induce antibodies against the HIV-1 derived multiepitope polypeptide TAB9. Vaccine 1999; 17: 2646-2650.
95. Cohen J. Bumps on the vaccine road. Science 1994; 265:1371-1373.